Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 9

    1.

    Adjuvant therapy for gastric cancer after D2 gastrectomy.

    Nishida T.

    Lancet. 2012 Jan 28;379(9813):291-2. Epub 2012 Jan 7. No abstract available.

    PMID:
    22226518
    [PubMed - indexed for MEDLINE]
    2.

    Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

    Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators.

    Lancet. 2012 Jan 28;379(9813):315-21. Epub 2012 Jan 7.

    PMID:
    22226517
    [PubMed - indexed for MEDLINE]
    3.

    The value of the National Health and Nutrition Survey in Japan.

    Sasaki S.

    Lancet. 2011 Oct 1;378(9798):1205-6. Epub 2011 Aug 30. No abstract available.

    PMID:
    21885109
    [PubMed - indexed for MEDLINE]
    4.

    Mass eradication of Helicobacter pylori: feasible and advisable?

    Mazzoleni LE, Francesconi CF, Sander GB.

    Lancet. 2011 Aug 6;378(9790):462-4. Epub 2011 Jul 21. No abstract available.

    PMID:
    21777975
    [PubMed - indexed for MEDLINE]
    5.

    Error occurred: cannot get document summary

    PMID:
    21093644

    6.

    Trastuzumab for gastric cancer treatment.

    Okines AF, Dewdney A, Chau I, Rao S, Cunningham D.

    Lancet. 2010 Nov 20;376(9754):1736; author reply 1736-7. No abstract available.

    PMID:
    21093643
    [PubMed - indexed for MEDLINE]
    7.

    Error occurred: cannot get document summary

    PMID:
    21093642

    8.

    Trastuzumab for gastric cancer treatment.

    Fujita T.

    Lancet. 2010 Nov 20;376(9754):1735; author reply 1735-6. No abstract available.

    PMID:
    21093641
    [PubMed - indexed for MEDLINE]
    9.

    Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

    Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators.

    Lancet. 2010 Aug 28;376(9742):687-97. Epub 2010 Aug 19. Erratum in: Lancet. 2010 Oct 16;376(9749):1302.

    PMID:
    20728210
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk